Argos HIV Immunotherapy Offers Potential Reprieve From Antiretrovirals
This article was originally published in Pharmaceutical Approvals Monthly
HIV patients armed with a new immunotherapy targeted at their personal viral load may be able to take a break from the oppression of antiretroviral therapy or even drop it altogether, if Argos Therapeutics' AGS-004 continues to meet with clinical success
You may also be interested in...
Six-year U.S. Army/NIH-sponsored study conducted in 16,000-plus Thai adults shows 31.2% decreased risk of infection, but better efficacy is needed.
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011